Zydus receives final approval from the USFDA for Clobetasol Propionate Lotion

Zydus receives final approval from the USFDA for Clobetasol Propionate Lotion Ahmedabad, 26 September, 2019 Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Lotion, (US RLD - Clobex Lotion ), 0.05%. This medication is used to treat a variety of skin conditions like eczema, psoriasis, dermatitis, allergies and rash. Clobetasol reduces the swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. The group now has 272 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare ther apies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗